Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(21):1507; doi:10.1093/jnci/djj475
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

IN THIS ISSUE

The first 10% of the full text of this article appears below.

PSA Velocity and Life-Threatening Prostate Cancer

Prostate-specific antigen (PSA) levels are currently used to screen men for prostate cancer, but a substantial number of men are overdiagnosed—they are treated for cancers that would not have become life-threatening. To determine whether the rate at which PSA levels change over time, or PSA velocity, is useful for screening men for life-threatening prostate cancer, Carter et al. (p. 1521) calculated the PSA velocities of 980 men enrolled in the Baltimore Longitudinal Study of Aging. The authors found that men with a high PSA velocity 10–15 years before their prostate cancer diagnosis had a greater . . . [Full Text of this Article]

Risk of New CNS Cancers in Childhood Cancer Survivors

Statins, Fibrates, and Risk of Melanoma

Vesicular Stomatitis Virus and Treatment of Glioma

EphA2 Agonist, Paclitaxel, and Ovarian Tumor Growth

Hormone Receptor Assays and Breast Cancer Prediction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?